Stay updated with breaking news from Ali Chartan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that Novavax...
Novavax's 2023-2024 season COVID vaccine candidate induced neutralizing responses to emerging subvariants EG.5.1 and XBB.1.16.6 in addition to XBB.1.5, XBB.1.16 and XBB.2.3Upon regulatory approval,...
Second quarter total revenue of $424 million and net income of $58 million Executed new strategic partnering agreement with SK bioscience, including an equity...
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax... | June 15, 2023
Novavax has developed a protein-based monovalent XBB.1.5 COVID vaccine candidate and is manufacturing at commercial scale with the intent to be in market during the fall vaccination campaignNovavax